Citation Impact
Citing Papers
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance
2003 Standout
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas
2006
Tumor irradiation enhances the tumor-specific distribution of poly(L-glutamic acid)-conjugated paclitaxel and its antitumor efficacy.
2000
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin
2002
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer
2004
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
2005
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice
2005
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Multifunctional Lipid/Quantum Dot Hybrid Nanocontainers for Controlled Targeting of Live Cells
2006 StandoutNobel
Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer
2005
Low prevalence of antibodies to glucose‐6‐phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
2003
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
2004
HPMA Copolymers Platinates Containing Dicarboxylato Ligands. Preparation, Characterisation and In Vitro and In Vivo Evaluation
2002
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
2005 StandoutNature
Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.
1997
Nanoparticles in Medicine: Therapeutic Applications and Developments
2007 Standout
Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma
2003
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
2004
PDEPT: polymer-directed enzyme prodrug therapy
2001
Polymer-drug conjugates: Recent development in clinical oncology
2008
Prodrug Strategies in Anticancer Chemotherapy
2007
Rationally Designed Chemical Modulators Convert a Bacterial Channel Protein into a pH‐Sensory Valve
2006 StandoutNobel
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
1994
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting
2001 Standout
Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity.
1998
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier
1995
Polymeric anticancer drugs with pH-controlled activation
2004
Colorectal cancer
2013 Standout
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
2003 Standout
Nanotheranostics ˗ Application and Further Development of Nanomedicine Strategies for Advanced Theranostics
2014
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells
2007
Evolving concepts of rheumatoid arthritis
2003 StandoutNature
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
2000
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Polymer conjugates as anticancer nanomedicines
2006 Standout
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
1998 Standout
Stimulated Release of Size‐Selected Cargos in Succession from Mesoporous Silica Nanoparticles
2012 StandoutNobel
Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
2005
Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors
2005
Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects*
1996
Systemic Lupus Erythematosus
2011 Standout
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Progress of drug-loaded polymeric micelles into clinical studies
2014
Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications
2012
Polymer-Based Cancer Nanotheranostics: Retrospectives of Multi-Functionalities and Pharmacokinetics
2013
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
HPMA copolymers: Origins, early developments, present, and future☆
2009
Application of Nanotechnology in Cancer Therapy and Imaging
2008
HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo
1999
Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
2005
The CDK inhibitors in cancer research and therapy
2011
Pancreatic Cancer
2010 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Biodegradable Polymers for Protein and Peptide Drug Delivery
1995
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
2009
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
2000 Standout
Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to Allergens
1989 Standout
Acute-Phase Proteins and Other Systemic Responses to Inflammation
1999 Standout
Organic Switches for Surfaces and Devices
2012 StandoutNobel
Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate
2004
Polymer–drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic
2001
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Anemia of Chronic Disease
2005 Standout
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer
2008
The dawning era of polymer therapeutics
2003 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
Cancer of the Ovary
2004 Standout
Natural Products as Leads to Potential Drugs: An Old Process or the New Hope for Drug Discovery?
2008
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
2006
Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles
2013 StandoutNobel
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Karyotypic complexity of the NCI-60 drug-screening panel.
2003
Therapeutic Nanoparticles for Drug Delivery in Cancer
2008 Standout
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
2001
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data
2003
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Intracellular Delivery of a Proapoptotic Peptide via Conjugation to a RAFT Synthesized Endosomolytic Polymer
2009
Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1)
1998
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Hydrogels for Tissue Engineering
2001 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
2001
INTRAPERITONEAL CHEMOTHERAPY
1994
Stabilization of Substances in Circulation
1998
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Preclinical evaluation of polymer-bound doxorubicin
1992
Gadolinium-Based Hybrid Nanoparticles as a Positive MR Contrast Agent
2006
Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis
1996
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
2002
Designing polymer conjugates as lysosomotropic nanomedicines
2007
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
2002
Distribution of IgE in a community population sample: correlations with age, sex, and allergen skin test reactivity
1981
Polyester Dendritic Systems for Drug Delivery Applications: In Vitro and In Vivo Evaluation
2002
Metal–Organic Frameworks in Biomedicine
2011 Standout
Systemic lupus erythematosus
2007
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Fluorine in medicinal chemistry: A review of anti-cancer agents
2006
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
2017 StandoutNobel
HPMA copolymer–aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines
2005
Works of J Cassidy being referenced
Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties
2011
Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours
1999
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
2004
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
2006
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
2011
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
1992
Novel Fluoropyrimidines: Improving the Efficacy and Tolerability of Cytotoxic Therapy
2004
Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.
1996
Synthetic Polymers Conjugated to Monoclonal Antibodies: Vehicles for Tumour-Targeted Drug Delivery
1991
Comparative genomic hybridization and chromosomal instability in solid tumours
1999
Serum IgE levels in patients with selective IgA deficiency.
1978
The association of autoimmune diseases and anti-IgA antibodies in patients with selective IgA deficiency.
1979
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
1999
Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity.
1995
Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
2002
Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation.
1977
A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis
1986